nach oben

Current Oncology Reports

Erschienen in:

01.12.2020 | Leukemia (A Aguayo, Section Editor)

Access to Therapy for Acute Myeloid Leukemia in the Developing World: Barriers and Solutions

verfasst von: Luis Antonio Meillon-Garcia, Roberta Demichelis-Gómez

Erschienen in: Current Oncology Reports | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Acute myeloid leukemia (AML) is a costly disease, and its impact is greater in developing countries (DC). We will review the current concept of what are DC, compare the differences in the epidemiology and economic burden of this disease between developed and DC, and finally, analyze the barriers and possible solutions that DC should implement to achieve better results.

Recent Findings

DC is a frequently misunderstood name. The way we use to measure human development is changing, and multidimension metrics better define what are DC. With this in mind, we show the differences in the AML epidemiology and the impact of economic burden in DC. We analyze the barriers to access therapy from a clinician point of view, to show that most DC shared similar challenges but with a diverse healthcare structure. Finally, we provide several possible solutions for a more integrated and timely treatment that allows better results not only in terms of survival but with a better quality of life.

Summary

The economic burden of AML treatment in DC is high, and the results are poor. It is crucial to face this challenge and propose new treatment approaches to achieve better results.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. https://doi.org/10.3322/caac.21442.CrossRef

• Vaughn JE, Shankaran V, Walter RB. Trends in clinical benefits and costs of novel therapeutics in AML: at what price does progress come? Curr Hematol Malignancy Rep. 2019;14:171–8. https://doi.org/10.1007/s11899-019-00510-2. This study analyzes the complexities of assessing costs versus benefits of AML treatment, emphasizing novel agents.CrossRef

Noone AM, Howlader N, Krapcho M, et al. SEER cancer statistics review, 1975–2015. Bethesda, MD: National Cancer Institute; 2018. based on November 2017 SEER data submission, posted to the SEER web site, April 2018. Available from: https://seer.cancer.gov/csr/1975_2015/.

Bewersdorf JP, Shallis RM, Wang R, Huntington SF, Perreault S, Ma X, et al. Healthcare expenses for treatment of acute myeloid leukemia. Expert Rev Hematol. 2019;12:641–50. https://doi.org/10.1080/17474086.2019.1627869.

Wang R, Zeidan AM, Halene S, Xu X, Davidoff AJ, Huntington SF, et al. Health care use by older adults with acute myeloid leukemia at the end of life. J Clin Oncol. 2017;35:3417–24. https://doi.org/10.1200/JCO.2017.72.7149.

National Cancer Institute. Drugs approved for acute myeloid leukemia. https://www.cancer.gov/about-cancer/treatment/drugs/leukemia#3.

Mahmoud D, Skikne BS, Kucmin-Bemelmans I, Alleman C, et al. Overall economic burden of total treatment costs in acute myeloid leukemia throughout the course of the disease. [abstract]. Blood. 2012;120:3614.CrossRef

Giebe SL, Labopin M, Ehninger G, Beelen D, Blaise D, Ganser A, et al. Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia. Blood. 2010;116:122–8. https://doi.org/10.1182/blood-2010-01-266478.CrossRef

• UNDP. 2018. 2018 Statistical update: human development indices and indicators. New York. http://hdr.undp.org/en/content/human-development-indices-indicators-2018-statistical-update. Accessed December 12^th, 2019. An up-to-date UNDP document that evaluates new human development indices in both developed and developing countries.

10.

http://hdr.undp.org/en/2019-report. Accessed December 21, 2019.

11.

Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, et al. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet. 2010;376:1186–93. https://doi.org/10.1016/S0140-6736(10)61152-X.

12.

• Todorovic V, Aapro M, Pavlidis N, Arsovski O, Belkacemi Y, Babovic N, et al. AROME-ESO Oncology Consensus Conference: access to cancer care innovations in countries with limited resources. Association of Radiotherapy and Oncology of the Mediterranean Area (AROME–Paris) and European School of Oncology (ESO – Milan). J BUON. 2019;24:2180–97. A consensus document with the objective to prioritize the access to treatments and innovations in the most common types of cancer in low-middle income Mediterranean countries.PubMed

13.

Hagiwara M, Sharma A, Chung KC, Delea TE. Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia. J Med Econ. 2018;21:1119–30. https://doi.org/10.1080/13696998.2018.1513847.CrossRefPubMed

14.

Jaime-Perez JC, Brito-Ramirez AS, Pinzon-Uresti MA, Gutierrez-Aguirre H, Cantu-Rodriguez OG, Herrera-Garza JL, et al. Characteristics and clinical evolution of patients with acute myeloblastic leukaemia in northeast Mexico: an eight-year experience at a university hospital. Acta Haematol. 2014;132:144–51. https://doi.org/10.1159/000356794.CrossRefPubMed

15.

Padilha SL, Souza EJ, Matos MC, Domino NR. Acute myeloid leukaemia: survival analysis of patients at a university hospital of Parana. Rev Bras Haematol Hemoter. 2015;37:21–7. https://doi.org/10.1159/000491989.CrossRef

16.

Meng CY, Noor PJ, Ismail A, Ahid MF, Zakaria Z. Cytogenetic profile of de novo acute myeloid leukaemia patients in Malaysia. Int J Biomed Sci. 2013;9:26–32.PubMedPubMedCentral

17.

Bahl A, Sharma A, Raina V, Kumar L, Bakhshi S, Gupta R, et al. Long-term outcomes for patients with acute myeloid leukaemia: a single center experience from AIIMS, India. Asia Pac J Clin Oncol. 2015;11:242–52. https://doi.org/10.1111/ajco.12333.

18.

Colunga-Pedraza PR, Gomez-Cruz GB, Colunga-Pedraza JE, Ruiz-Argüelles GJ. Geographic hematology: some observations in Mexico. Acta Haematol. 2018;140:114–20. https://doi.org/10.1159/000491989.CrossRefPubMed

19.

Gomez-Almaguer D, Marcos-Ramirez ER, Montano-Figueroa EH, Ruiz-Arguelles GJ, Best-Aguilera CR, Lopez-Sanchez MD, et al. Acute leukaemia characteristics are different around the world: the Mexican perspective. Clin Lymphoma Myeloma Leuk. 2017;17:46–51. https://doi.org/10.1016/j.clml.2016.09.003.CrossRefPubMed

20.

Douer D, Preston-Martin S, Chang E, Nichols PW, Watkins KJ, Levine AM. High frequency of acute promyelocytic leukaemia among Latinos with acute myeloid leukaemia. Blood. 1996;87:308–13. https://doi.org/10.1182/blood.V87.1.308.308.CrossRefPubMed

21.

Rego EM, Jacomo RH. Epidemiology and treatment of acute promyelocytic leukaemia in latin america. Mediterr J Haematol Infect Dis. 2011;3:e2011049.CrossRef

22.

Otero JC, Santillana S, Fereyros G. High frequency of acute promyelocytic leukaemia among Latinos with acute myeloid leukaemia. Blood. 1996;88:377. https://doi.org/10.1182/blood.V88.1.377a.377a.CrossRefPubMed

23.

Li S, Chen L, Jin W, Ma X, Ma Y, Dong F, et al. Influence of body mass index on incidence and prognosis of acute myeloid leukaemia and acute promyelocytic leukaemia: a metaanalysis. Sci Rep. 2017;7:17998. https://doi.org/10.1038/s41598-017-18278-x.

24.

Ruiz-Arguelles GJ, Garces-Eisele J, Reyes-Nunez V, Gomez-Rangel JD, Ruiz-Delgado GJ. More on geographic haematology: the breakpoint cluster regions of the PML/RAR alpha fusion gene in Mexican mestizo patients with promyelocytic leukaemia are different from those in Caucasians. Leuk Lymphoma. 2004;45:1365–8. https://doi.org/10.1080/10428190310001657344.CrossRefPubMed

25.

• Rego EM, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte M, del Rosario Uriarte R, et al. Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood. 2013;121(11):1935–43. https://doi.org/10.1182/blood-2012-08-449918. Describe the procedure of this initiative in some developing countries to reach better results in the management of APL.

26.

Ruiz-Arguelles GJ, Marin-Lopez A, Lobato-Mendizabal E, Ruiz-Arguelles A, Nichols WL, Katzman JA. Acute megakaryoblastic leukaemia: a prospective study of its identification and treatment. Br J Haematol. 1986;62:55–63 doi.org/dpfwg6.10.CrossRef

27.

Hagiwara M, Sharma A, Chung KC, Delea TE. Burden of acute myeloid leukemia (AML) in a U.S. commercially insured population. J Clin Oncol. 2017;35(15(suppl)):e18330. https://doi.org/10.1080/13696998.2018.1513847.CrossRef

28.

•• Wiese M, Daver N. Unmet clinical needs and economic burden of disease in the treatment landscape of acute myeloid leukemia. Am J Manag Care. 2018;24(1Suppl):S347–55. A comprehensive review of the current treatment aspects of AML, including management, economic burden and unmet patient needs.

29.

Vaughn JE, Othus M, Powell MA, Gardner KM, Rizzuto DL, Hendrie PC, et al. Resource utilization and safety of outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia or myelodysplastic syndrome: a nonrandomized clinical comparative analysis. JAMA Oncol. 2015;1:1120–7. https://doi.org/10.1001/jamaoncol.2015.2969.

30.

Bosshard R, O'Reilly K, Ralston S, Chadda S, Cork D. Systematic reviews of economic burden and health-related quality of life in patients with acute myeloid leukemia. Cancer Treat Rev. 2018;69:224–32. https://doi.org/10.1016/j.ctrv.2018.07.005.CrossRefPubMed

31.

Thomas X, Le Jeune C. Treatment of elderly patients with acute myeloid leukemia. Curr Treat Options in Oncol. 2017;18:1–16. https://doi.org/10.1007/s11864-017-0445-5.CrossRef

32.

Stein EM, Bonifacio G, Latremouille-Viau D, Guerin A, Shi S, Gagnon-Sanschagri P, et al. Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and medicare populations. J Med Econ. 2018;21:556–63. https://doi.org/10.1080/13696998.2018.1425209.

33.

Bae YH, Mullins CD. Do value thresholds for oncology drugs differ from nononcology drugs? J Manag Care Spec Pharm. 2014;20:1086–92. https://doi.org/10.18553/jmcp.2014.20.11.1086.CrossRefPubMed

34.

LeBlanc TW, Fish LJ, Bloom CT, et al. Patient experiences of acute myeloid leukemia: a qualitative study about diagnosis, illness understanding, and treatment decision-making. Psychooncology. 2017;26(12):2063–8. https://doi.org/10.1002/pon.4309.CrossRefPubMed

35.

Ding T, Wang X, Fu A, Xu L, Lin J. Anxiety and depression predict unfavorable survival in acute myeloid leukemia patients. Medicine. 2019;98:e17314. https://doi.org/10.1097/MD.0000000000017314.CrossRefPubMedPubMedCentral

36.

Byrne MM, Halman LJ, Koniaris LG, Cassileth PA, Rosenblatt JD, Cheung MC. Effects of poverty and race on outcomes in acute myeloid leukemia. Am J Clin Oncol. 2011;34:297–304. https://doi.org/10.1097/COC.0b013e3181dea934.CrossRefPubMed

37.

Bradley CJ, Dahman B, Jin Y, Shickle LM, Ginder GD. Acute myeloid leukemia: how the uninsured fare. Cancer. 2011;117:4772–8. https://doi.org/10.1002/cncr.26095.CrossRefPubMed

38.

Sekeres MA, Peterson B, Dodge RK, Mayer RJ, Moore JO, Lee EJ, et al. Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood. 2004;103:4036–42. https://doi.org/10.1182/blood-2003-09-3118.

39.

Kristinsson SY, Derolf AR, Edgren G, Dickman PW, Björkholm M. Socioeconomic differences in patient survival are increasing for acute myeloid leukemia and multiple myeloma in Sweden. J Clin Oncol. 2009;27:2073–80. https://doi.org/10.1200/JCO.2008.18.2006.CrossRefPubMed

40.

Østgård LSG, Nørgaard M, Medeiros BC, Friis LS, Schoellkopf C, Severinsen MT, et al. Effects of education and income on treatment and outcome in patients with acute myeloid leukemia in a tax-supported health care system: a national population-based cohort study. J Clin Oncol. 2017;35(32):3678–87. https://doi.org/10.1200/JCO.2017.73.6728.

41.

Berger E, Delpierre C, Despas F, Bertoli S, Bérard E, Bombarde O, et al. Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients. BMC Cancer. 2019;19(1):883. https://doi.org/10.1186/s12885-019-6093-3.

42.

• Benicio MTL, Ribeiro AFT, Américo AD, Furtado FM, Glória AB, Lima AS, et al. Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle-income countries (LMIC): a Brazilian experience. Leuk Res. 2017;60:109–14. https://doi.org/10.1016/j.leukres.2017.07.005. A comprehensive document that shows the poorer results of ELN recommendations in low-middle outcome nation like Brazil.CrossRefPubMed

43.

Demichelis R, Zapata N, Leyto F, Terreros E, Carrillo A, Montaño E, et al. Survival analysis of adult patients with acute myeloid leukemia (AML) treated with intensive chemotherapy: results of a Mexican national AML registry. Clin Lymphoma Myeloma Leuk. 2019;19(1):S209–10. https://doi.org/10.1016/j.clml.2019.07.074.

44.

Philip C, George B, Ganapule A, Korula A, Jain P, Alex AA, et al. Acute myeloid leukaemia: challenges and real world data from India. Br J Haematol. 2015;170:110–7. https://doi.org/10.1111/bjh.13406.

45.

Jacob S, Jacob SE, Suryanarayana BS, Dutta TK. Clinical profile and short term outcome of adult patients with acute myeloid leukemia. Indian J Hematol Blood Transfus. 2019;35(3):431–6. https://doi.org/10.1007/s12288-018-1051-9.CrossRefPubMed

46.

Govind BK, Chethan R, Lakshmaiah KC, Lokanatha D, Linu AJ, Suresh BMC, et al. Treatment patterns and comparative analysis of non-intensive regimens in elderly acute myeloid leukemia patients—a real-world experience from India. Ann Hematol. 2019;98:881–8. https://doi.org/10.1007/s00277-019-03600-6.CrossRef

47.

Sekeres MA, Elson P, Kalaycio ME, Advani AS, Copelan EA, Faderl S, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 2009;113:28–36. https://doi.org/10.1182/blood-2008-05-157065.

48.

Garnica M, Sinhorelo A, Madeira L, Portugal R, Nucci M. Diagnostic-driven antifungal therapy in neutropenic patients using the D-index and serial serum galactomannan testing. Braz J Infect Dis. 2016;20:354–9. https://doi.org/10.1016/j.bjid.2016.04.007.CrossRefPubMed

49.

Neofytos D, Lu K, Hatfield-Seung A, Blackford A, Marr KA, Treadway S, et al. Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy. Diagn Microbiol Infect Dis. 2013;75(2):144–9. https://doi.org/10.1016/j.diagmicrobio.2012.10.001.CrossRefPubMed

50.

Lien MY, Chia-Hui C, Ching-Chan L, Li-Yuan B, Chang-Fang C, Su-Peng Y, et al. Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: a retrospective cohort study. PLoS ONE. 13(6):e0197851. https://doi.org/10.1371/journal.pone.0197851.

51.

https://www.inegi.org.mx/temas/derechohabiencia/ entered on Dec 1, 2019.

52.

Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454–64. https://doi.org/10.1056/NEJMoa1614359.

53.

Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2019;104(1):113–9. https://doi.org/10.3324/haematol.2018.188888.

54.

Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus Daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684–92. https://doi.org/10.1200/JCO.2017.77.6112.

55.

Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–31. https://doi.org/10.1182/blood-2017-04-779405.CrossRefPubMedPubMedCentral

56.

DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–98. https://doi.org/10.1056/NEJMoa1716984.CrossRefPubMed

57.

Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–40. https://doi.org/10.1056/NEJMoa1902688.

58.

Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33(2):379–89. https://doi.org/10.1038/s41375-018-0312-9.

59.

DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17. https://doi.org/10.1182/blood-2018-08-868752.CrossRefPubMedPubMedCentral

60.

Wei AH, Strickland SA Jr, Hou JZ, Fiedler W, Lin TL, Walter RB, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol. 2019;37(15):1277–84. https://doi.org/10.1200/JCO.18.01600.CrossRefPubMedPubMedCentral

61.

https://data.worldbank.org/country. Entered on Dec 1. 2019.

62.

https://clinicaltrials.gov/ct2/home. Entered on Dec 1, 2019.

63.

Correa de Araujo Koury L, Ganser A, Berliner N, Rego EM. Treating acute promyelocytic leukaemia in Latin America: lessons from the international consortium on acute Leukaemia experience. Br J Haematol. 2017;177:979–83. https://doi.org/10.1111/bjh.14589.CrossRefPubMed

64.

Aljuaid M, Mannan F, Chaudhry Z, Rawaf S, Majeed A. Quality of care in university hospitals in Saudi Arabia: a systematic review. BMJ Open. 2016;6:e008988. https://doi.org/10.1136/bmjopen-2015-008988.CrossRefPubMedPubMedCentral

65.

Mort E, Bruckel J, Donelan K, Paine L, Rosen M, Thompson D, et al. Improving health care quality and patient safety through peer-to-peer assessment: demonstration project in two academic medical centers. Am J Med Qual. 2017;32:472–9. https://doi.org/10.1177/1062860616673709.

66.

Sala Torra O, Beppu L, Smith JL, Welden L, Georgievski J, Gupta K, et al. Paper or plastic? BCR-ABL1 quantitation and mutation detection from dried blood spots. Blood. 2016;127:2773–4. https://doi.org/10.1182/blood-2015-12-689059.

67.

Drain PK, Hyle EP, Noubary F, Freedberg KA, Wilson D, Bishai WR, et al. Diagnostic point-of-care tests in resource-limited settings. Lancet Infect Dis. 2014;14(3):239–49. https://doi.org/10.1016/S1473-3099(13)70250-0.

68.

Hashimoto Y, Hatayama Y, Kojima N, Morishita S, Matsumoto S, Hosoda Y, et al. Development of reverse transcription loop-mediated isothermal amplification for simple and rapid detection of promyelocytic leukemia-retinoic acid receptor a mRNA. Yonago Acta Med. 2016;59(4):262–9.

69.

https://www.gsmaintelligence.com/research/ Accessed Jan 7, 2020.

70.

Leymarie V, Flandrin G, Noguera ME, Leymarie F, Lioure B, Daliphard S, et al. Telehematology: a pilot experience of cytological diagnosis of acute myeloid leukemia via the Internet. A GOELAMS study. Haematologica. 2006;91:1285–6.

71.

Mehdizadeh H, Asadi F, Mehrvar A, Nazemi E, Emami H. Smartphone apps to help children and adolescents with cancer and their families: a scoping review. Acta Oncol. 2019;58(7):1003–14. https://doi.org/10.1080/0284186X.2019.1588474.CrossRefPubMed

72.

Abu Arja MH, Stanek JR, Morales La Madrid AE, Lassaletta A, Bartels U, Qaddoumi I, et al. The Latin American brain tumor board teleconference: results of a web-based survey to evaluate participant experience utilizing this resource. Childs Nerv Syst. 2019;35(2):257–65. https://doi.org/10.1007/s00381-018-4000-x.CrossRefPubMed

73.

Malhotra H, Radich J, Garcia-Gonzalez P. Meeting the needs of CML patients in resource-poor countries. ASH Educ Program. 2019:433–42.

Titel: Access to Therapy for Acute Myeloid Leukemia in the Developing World: Barriers and Solutions
verfasst von: Luis Antonio Meillon-Garcia
Roberta Demichelis-Gómez
Publikationsdatum: 01.12.2020
Verlag: Springer US
Erschienen in: Current Oncology Reports / Ausgabe 12/2020
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-020-00987-8

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Access to Therapy for Acute Myeloid Leukemia in the Developing World: Barriers and Solutions

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2020

How Should We Approach Locally Advanced Squamous Cell Carcinoma of Head and Neck Cancer Patients Ineligible for Standard Non-surgical Treatment?

Multidisciplinary Outpatient Cancer Rehabilitation Can Improve Cancer Patients’ Physical and Psychosocial Status—a Systematic Review

The Combined Use of SBRT and Immunotherapy—a Literature Review

Combined Inhibition of EGFR and VEGF Pathways in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Synovial Sarcoma: A Complex Disease with Multifaceted Signaling and Epigenetic Landscapes

Extended Endocrine Therapy for Early-Stage Breast Cancer: How Do We Decide?

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie